skip to main content

Refractory overactive bladder with urge urinary incontinence — MSRA MCQ

Instant feedback + full explanation. One question, done properly.

HardLUTSRefractory overactive bladder with urge urinary incontinenceMSRA

A 63-year-old woman has urgency, daytime frequency and urge urinary incontinence. A 3-day bladder diary shows 13 small-volume voids daily, each preceded by urgency. Urine culture is negative, post-void residual volume is 45 mL, and pelvic examination shows no prolapse or demonstrable stress incontinence. She completed a supervised 6-week bladder-training programme and reduced caffeine intake without adequate benefit. Solifenacin and tolterodine were each stopped after 6 weeks because of no meaningful improvement despite adherence. Mirabegron 50 mg once daily and subsequently vibegron 75 mg once daily were also ineffective after adequate trials. She has no neurological disease, voiding difficulty, haematuria or recurrent UTI. She wishes to discuss invasive treatment and confirms that she would be willing to perform clean intermittent catheterisation if necessary. What is the most appropriate next management step?

Educational content. Not a substitute for clinical judgement or local policy.

Reveal the answer and explanation

Correct answer: C — Refer for urodynamic investigation to establish whether detrusor overactivity is present before selecting an invasive treatment

This woman has clinically diagnosed overactive bladder with urge urinary incontinence, supported by urgency-associated small-volume frequency, negative microbiology and a low residual volume. She has appropriately failed behavioural treatment and multiple medicines, including anticholinergics and beta-3 agonists, and now wishes to consider invasive management. At this point, NICE recommends urodynamic investigation to determine whether detrusor overactivity is causing the symptoms before choosing an invasive treatment. If detrusor overactivity is demonstrated, an invasive option can then be considered through the appropriate specialist pathway. Her willingness to undertake clean intermittent catheterisation is relevant to subsequent counselling for botulinum toxin, but does not remove the requirement for urodynamic assessment first. Botulinum toxin type A is not the immediate next step because it should follow confirmation of the relevant urodynamic diagnosis and local MDT review. Percutaneous sacral nerve stimulation is generally considered after botulinum toxin has failed or when the patient is unwilling to accept catheterisation risk. Posterior tibial nerve stimulation is reserved for selected women after MDT review who do not want botulinum toxin or sacral nerve stimulation. A further immediate-release oxybutynin trial is inappropriate after unsuccessful trials of two anticholinergics and beta-3 agonists.

Reference: NICE NG123: Urinary incontinence and pelvic organ prolapse in women: management — invasive procedures for overactive bladder (2019; checked 16 August 2026) — https://www.nice.org.uk/guidance/ng123/chapter/recommendations NICE NG123: Urinary incontinence and pelvic organ prolapse in women: management — botulinum toxin type A and percutaneous sacral nerve stimulation (2019; checked 16 August 2026) — https://www.nice.org.uk/guidance/ng123/chapter/recommendations